US 11,858,964 B2
Virus-inspired compositions and methods of redirecting preexisting immune responses using the same for treatment of cancer
Joshua Weiyuan Wang, Alexandria, VA (US); Ken Matsui, Frederick, MD (US); Philip Alan Storm, Redwood City, CA (US); and Kristin Marie Peters, Reisterstown, MD (US)
Assigned to VerImmune Inc., Washington, DC (US)
Filed by VerImmune Inc., Washington, DC (US)
Filed on Oct. 19, 2021, as Appl. No. 17/505,466.
Claims priority of provisional application 63/220,485, filed on Jul. 10, 2021.
Claims priority of provisional application 63/093,525, filed on Oct. 19, 2020.
Prior Publication US 2022/0135624 A1, May 5, 2022
Int. Cl. A61K 39/00 (2006.01); A61K 39/12 (2006.01); A61K 39/295 (2006.01); A61K 39/155 (2006.01); C07K 14/005 (2006.01); C12N 7/00 (2006.01); A61P 35/00 (2006.01)
CPC C07K 14/005 (2013.01) [A61K 39/0011 (2013.01); A61K 39/12 (2013.01); A61K 39/295 (2013.01); A61P 35/00 (2018.01); C12N 7/00 (2013.01); A61K 2039/585 (2013.01); A61K 2039/6075 (2013.01); A61K 2039/6081 (2013.01); A61K 2039/70 (2013.01); C07K 2319/50 (2013.01); C12N 2710/20022 (2013.01); C12N 2710/20034 (2013.01); C12N 2710/20052 (2013.01)] 26 Claims
 
1. A composition, comprising:
a plurality of virus proteins, wherein each of said plurality of virus proteins comprises a mutated amino acid sequence of a Papillomaviridae L1 protein;
one or more peptides each comprising one or more epitopes from one or more pathogens other than a Papillomaviridae antigenic peptide;
wherein the mutated amino acid sequence of the Papillomaviridae L1 protein comprises at least the following mutations with respect to the wild type L1 protein sequence: (a) a deletion of at least five amino acid residues from an amino-terminus, (b) a deletion of at least ten amino acid residues from the helix four region, and (c) a deletion of at least thirty amino acid residues from a carboxy-terminus,
wherein the one or more peptides are attached to the plurality of virus proteins, and
wherein said plurality of virus proteins spontaneously assemble to form an icosahedron or dodecahedron capsid having a triangulation number T equal to 1 that binds to proteoglycan expressed on tumor cells.